原发性肝癌系统性化疗的临床进展  

Clinical advance in systemic chemotherapy for primary liver cancer

作　　者：杨葛亮[1] 翟笑枫[1] 

机构地区：[1]第二军医大学长海医院中医系,上海200433

出　　处：《肿瘤》2014年第1期91-96,共6页Tumor

基　　金：上海市中医药事业发展三年行动计划重大研究项目(编号:ZYSNXD-CC-ZDYJ032);上海市科学技术委员会科研计划项目(编号:12401907800)

摘　　要：原发性肝癌是临床上常见的恶性肿瘤。由于早期诊断率低,大多数患者确诊时已至中晚期,失去了手术根治机会。目前,提倡综合治疗来改善患者预后,延长生存期。近年来,随着新一代化疗药物的上市及靶向治疗的推出,系统性化疗已越来越受到重视。大量的临床试验结果表明,系统性化疗治疗肝癌在延长患者生存期、控制疾病发展以及提高生存质量方面具有重要的实际意义。本文就目前原发性肝癌系统性化疗的临床治疗进展及存在问题等进行综述。Primary liver cancer （PLC） is one kind of common malignant tumor. Due to its low rate of early diagnosis, most patients are preliminarily diagnosed of advanced cancer and have lost opportunities for radical surgery. Currently, the integrated treatment is applied to improve the prognosis of these patients and prolong the survival time. Recently, more attentions have been paid to systemic chemotherapy with the development of new generation of chemotherapeutic agents and the targeted therapy. A large number of clinical trials have revealed that systemic chemotherapy plays an important role in the treatment of PLC, including prolonging the survival time, controlling the development of cancer and improving the quality of life. This review summarizes the advance in systemic chemotherapy for PLC and the related issues.

关 键 词：肝肿瘤 药物疗法 联合 肿瘤治疗方案 靶向治疗 

分 类 号：R735.7[医药卫生—肿瘤]